About Spirogen
Spirogen is a Healthcare company based in London (United Kingdom) founded in 2001, and was acquired by MedImmune in October 2013. Antibody-drug conjugates to target cancer stem cells. Its focus areas include Life Sciences, Oncology, Drugs and Diversified.
Company details
Founded in 2001 in London, United Kingdom, Spirogen operated in the biotechnology sector focused on oncology. Proprietary pyrrolobenzodiazepine technology was utilized to create antibody-drug conjugates aimed at cancer stem cells. Partnerships were established with entities including Genentech, Seattle Genetics, ADC Therapeutics, Auven Therapeutics, Kolltan Pharmaceuticals, and Mitsubishi Tanabe Pharma. Acquisition by AstraZeneca and MedImmune occurred in 2013.
- Headquarters London, United Kingdom
- Stage Acquired
- SectorsHealthcare
- Website spirogen.com
- Acquired by MedImmune (Oct 2013)
Investors in Spirogen
Spirogen has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include MedImmune.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Biologic R&D for oncology; respiratory, inflammation and autoimmune; and cardiovascular and metabolic diseases | 1987 | medimmune.com | Gaithersburg, United States |
Investor details for Spirogen
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Spirogen
2 dated milestones of Spirogen across 12 years, from founding to its latest funding, stage changes and deals.
- Founded Spirogen is founded.
- Exit Acquired by MedImmune.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Spirogen
Spirogen was founded in 2001.
Spirogen is headquartered in London, United Kingdom. It is registered at London, England, United Kingdom.
Founded in 2001 in London, United Kingdom, Spirogen operated in the biotechnology sector focused on oncology. Proprietary pyrrolobenzodiazepine technology was utilized to create antibody-drug conjugates aimed at cancer stem cells. Partnerships were established with entities including Genentech, Seattle Genetics, ADC Therapeutics, Auven Therapeutics, Kolltan Pharmaceuticals, and Mitsubishi Tanabe Pharma. Acquisition by AstraZeneca and MedImmune occurred in 2013.
Spirogen has 1 investor. Key investors include MedImmune.
Yes. Spirogen was acquired by MedImmune in October 2013.